Advances in Molecular Docking Techniques for Targeting Protein Misfolding in Neurodegenerative Diseases.

IF 2.2 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Kuldeep Singh, Jeetendra Kumar Gupta, Shiv Narayan, Ketki Rani, Divya Jain, Prateek Porwal, Mukesh Chandra Sharma, Shivendra Kumar
{"title":"Advances in Molecular Docking Techniques for Targeting Protein Misfolding in Neurodegenerative Diseases.","authors":"Kuldeep Singh, Jeetendra Kumar Gupta, Shiv Narayan, Ketki Rani, Divya Jain, Prateek Porwal, Mukesh Chandra Sharma, Shivendra Kumar","doi":"10.2174/0113892010298545241108062449","DOIUrl":null,"url":null,"abstract":"<p><p>Neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease, represent a significant global health challenge with limited therapeutic options. Protein misfolding and aggregation, a common pathological hallmark in these disorders, have emerged as promising targets for therapeutic intervention. Molecular docking techniques have played a pivotal role in the identification and design of small molecules that can modulate protein misfolding, offering new hope for effective treatments. This review provides an overview of recent advancements in molecular docking techniques for targeting protein misfolding in neurodegenerative diseases. We discuss the principles and methodologies behind molecular docking, including various scoring functions and algorithms employed for accurate ligand-protein interactions. Additionally, we explore the use of molecular dynamics simulations and machine learning approaches to enhance the precision of docking studies. Furthermore, we highlight case studies and success stories where molecular docking has contributed to the discovery of potential drug candidates for neurodegenerative diseases. These include compounds that inhibit amyloid-β aggregation in Alzheimer's disease, α-synuclein oligomerisation in Parkinson's disease, and mutant huntingtin aggregation in Huntington's disease. We also discuss the problems and restrictions of molecular docking related to neurodegenerative diseases, such as how to accurately show the flexibility of proteins and why docking results need to be confirmed by experiments. We also discuss the structural biology methods, such as cryo-electron microscopy and X-ray crystallography, and how these techniques might help in improving molecular docking studies.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010298545241108062449","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease, represent a significant global health challenge with limited therapeutic options. Protein misfolding and aggregation, a common pathological hallmark in these disorders, have emerged as promising targets for therapeutic intervention. Molecular docking techniques have played a pivotal role in the identification and design of small molecules that can modulate protein misfolding, offering new hope for effective treatments. This review provides an overview of recent advancements in molecular docking techniques for targeting protein misfolding in neurodegenerative diseases. We discuss the principles and methodologies behind molecular docking, including various scoring functions and algorithms employed for accurate ligand-protein interactions. Additionally, we explore the use of molecular dynamics simulations and machine learning approaches to enhance the precision of docking studies. Furthermore, we highlight case studies and success stories where molecular docking has contributed to the discovery of potential drug candidates for neurodegenerative diseases. These include compounds that inhibit amyloid-β aggregation in Alzheimer's disease, α-synuclein oligomerisation in Parkinson's disease, and mutant huntingtin aggregation in Huntington's disease. We also discuss the problems and restrictions of molecular docking related to neurodegenerative diseases, such as how to accurately show the flexibility of proteins and why docking results need to be confirmed by experiments. We also discuss the structural biology methods, such as cryo-electron microscopy and X-ray crystallography, and how these techniques might help in improving molecular docking studies.

靶向神经退行性疾病蛋白错误折叠的分子对接技术研究进展
神经退行性疾病,如阿尔茨海默病、帕金森病和亨廷顿病,是一项重大的全球健康挑战,治疗方案有限。蛋白质错误折叠和聚集是这些疾病的常见病理标志,已成为治疗干预的有希望的目标。分子对接技术在调节蛋白质错误折叠的小分子识别和设计中发挥了关键作用,为有效治疗提供了新的希望。本文综述了神经退行性疾病中靶向蛋白错误折叠的分子对接技术的最新进展。我们讨论了分子对接背后的原理和方法,包括用于精确配体-蛋白质相互作用的各种评分函数和算法。此外,我们探索使用分子动力学模拟和机器学习方法来提高对接研究的精度。此外,我们重点介绍了分子对接有助于发现神经退行性疾病潜在候选药物的案例研究和成功案例。这些化合物包括在阿尔茨海默病中抑制淀粉样蛋白-β聚集,在帕金森病中抑制α-突触核蛋白寡聚化,在亨廷顿病中抑制突变亨廷顿蛋白聚集。我们还讨论了与神经退行性疾病相关的分子对接存在的问题和限制,例如如何准确地显示蛋白质的灵活性以及对接结果为什么需要通过实验来证实。我们还讨论了结构生物学方法,如低温电子显微镜和x射线晶体学,以及这些技术如何有助于改进分子对接研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current pharmaceutical biotechnology
Current pharmaceutical biotechnology 医学-生化与分子生物学
CiteScore
5.60
自引率
3.60%
发文量
203
审稿时长
6 months
期刊介绍: Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include: DNA/protein engineering and processing Synthetic biotechnology Omics (genomics, proteomics, metabolomics and systems biology) Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes) Drug delivery and targeting Nanobiotechnology Molecular pharmaceutics and molecular pharmacology Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes) Pharmacokinetics and pharmacodynamics Applied Microbiology Bioinformatics (computational biopharmaceutics and modeling) Environmental biotechnology Regenerative medicine (stem cells, tissue engineering and biomaterials) Translational immunology (cell therapies, antibody engineering, xenotransplantation) Industrial bioprocesses for drug production and development Biosafety Biotech ethics Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信